Akeso (09926): AstraZeneca’s US$2bn Summit investment strengthens the strategic case for Akeso’s ivonescimab

Overview

This event-driven Akeso report assesses what AstraZeneca’s US$2bn strategic equity investment in Summit Therapeutics means for ivonescimab, Akeso’s PD-1/VEGF bispecific antibody licensed to Summit outside China. JPMorgan argues that the deal supports the asset’s global value and development outlook while Akeso approaches several important data and regulatory catalysts.

Core views

JPMorgan considers AstraZeneca’s US$2bn strategic equity investment in Summit Therapeutics, alongside a clinical collaboration, a clear external validation event for ivonescimab. Akeso developed the PD-1/VEGF bispecific antibody and licensed it to Summit for development outside China. The investment is being made through convertible preferred shares at US$18.36 per common-share equivalent, an 18.6% premium to Summit’s September 28 close. It is expected to represent roughly 12% of Summit’s outstanding common stock, or just under 11% on a fully diluted basis if converted or exercised. JPMorgan notes that reports in 2025 had indicated that AstraZeneca explored a licensing partnership with Summit, making the new transaction directionally consistent with prior interest but materially more concrete. The report’s central conclusion is that AstraZeneca is committing capital and collaboration resources before two potentially high-risk ivonescimab milestones: the November 14 PDUFA date for second-line-or-later EGFR-positive NSCLC and final Phase 3 PFS data from the HARMONi-3 squamous NSCLC cohort expected in 4Q26. JPMorgan views this timing as evidence of AstraZeneca’s confidence in the asset’s longer-term strategic value, its probability of US approval, and the prospect of positive HARMONi-3 results. The report nevertheless notes that one or both events could create negative headline risk for Summit and ivonescimab. The collaboration is intended to combine ivonescimab with AstraZeneca’s antibody-drug conjugate portfolio, including its CLDN18.2 ADC in gastrointestinal cancers. JPMorgan believes this can broaden ivonescimab’s role beyond monotherapy and standard immuno-oncology-plus-chemotherapy settings. For Akeso, the firm sees additional Summit funding and access to AstraZeneca’s ADC platform as potentially accelerating and expanding ex-China Phase 3 development. That broader global momentum could support Akeso’s retained China franchise, royalty and milestone economics, and investor perception of the asset. While Summit already has clinical collaborations with GSK, Revolutionary Medicine and Arcus, JPMorgan highlights that AstraZeneca is the first to make a significant equity investment in Summit; further evidence of a deeper AZN/Summit collaboration would be positive for Akeso. Near-term attention centers on HARMONi-GI1 Phase 3 biliary tract cancer data at the ESMO 2026 Presidential Symposium II on October 25. Akeso has disclosed that the study met its primary overall-survival endpoint, and JPMorgan expects the OS hazard ratio could be at or below 0.6; confirmation would, in its view, provide strong validation of ivonescimab beyond NSCLC. The subsequent November 14 PDUFA decision and HARMONi-3 final PFS readout remain the next major clinical and regulatory tests. JPMorgan retains its Overweight rating and HK$125 Dec-2027 target price for Akeso. Its broader thesis includes China-market expansion for AK104, with approximately RMB7bn projected China peak sales, and AK112’s potential NRDL inclusion and China sales momentum, also with more than RMB7bn projected China peak sales. The firm expects AK112’s competitive efficacy profile versus Keytruda and leadership in the PD-(L)1/VEGF field to support ex-China peak sales of more than US$5bn. The HK$125 target uses a DCF framework that forecasts free cash flow through 2034, with a 3.0% terminal growth rate and 9.6% WACC.

Analysis framework

JPMorgan first interprets the transaction structure, premium and timing as evidence of AstraZeneca’s view of ivonescimab. It then links the collaboration to potential clinical-development expansion, assesses upcoming regulatory and trial catalysts, and frames the implications for Akeso’s China franchise and ex-China economics. The price target is supported by a discounted-cash-flow valuation using explicit free-cash-flow, discount-rate and terminal-growth assumptions.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  JPMorgan estimates Akeso’s free cash flow through 2034 and discounts it using a 9.6% WACC and 3.0% terminal growth rate to derive its HK$125 per-share valuation.

• Corporate Fundamentals and FinanceFCFF/FCFE Free Cash Flow

  Free-cash-flow forecast

  The valuation explicitly relies on projected Akeso free cash flow through 2034, with cash, debt, minority interest, early-pipeline assets and Summit equity value incorporated into equity value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Akeso (9926.HK)

  Primary covered company and developer of ivonescimab, licensed to Summit outside China.

  Strengths

  AstraZeneca’s investment is viewed as validation of ivonescimab; AK104 and AK112 have substantial projected China and ex-China sales opportunities.

  Comparison

  JPMorgan cites AK112’s highly competitive efficacy profile versus Keytruda.

  Risks

  Pipeline development setbacks and AK104 or AK112 sales below JPMorgan expectations.

• Summit Therapeutics

  Ex-China licensee and development partner for ivonescimab; recipient of AstraZeneca’s investment and collaboration.

  Strengths

  The investment provides additional capital and resources for ex-China Phase 3 trials and ADC-combination studies.

  Weaknesses

  Upcoming regulatory and HARMONi-3 catalysts may create negative headline risk.

  Comparison

  AstraZeneca is the first collaborator cited by JPMorgan to make a significant equity investment in Summit.

  Risks

  Potential negative outcomes from the November 14 PDUFA decision or HARMONi-3 final PFS data.

• AstraZeneca (AZN)

  Strategic investor in Summit and prospective ADC-combination collaborator for ivonescimab.

  Strengths

  Its ADC portfolio could broaden ivonescimab’s potential use cases, including in gastrointestinal cancers.

Key data

• AstraZeneca investment in SummitUS$2bnStrategic equity investment paired with a clinical collaboration around ivonescimab.
• Convertible preferred share priceUS$18.36 per common-share equivalentRepresents an 18.6% premium to Summit’s September 28 close.
• AstraZeneca expected Summit ownershipAbout 12% outstanding; just under 11% fully dilutedAssumes conversion or exercise of the preferred shares.
• Akeso price targetHK$125.00Dec-2027 target based on DCF valuation.
• DCF assumptions9.6% WACC; 3.0% terminal growth rateFree cash flow is estimated through 2034.
• AK104 China peak sales estimate~RMB7bnDriven by expected indication expansion across large China markets.
• AK112 sales estimates>RMB7bn China peak sales; US$5bn+ ex-China peak salesThe China outlook assumes successful NRDL inclusion; the ex-China outlook reflects its efficacy profile and PD-(L)1/VEGF positioning.

Impact & implications

JPMorgan believes the AZN/Summit transaction increases confidence in ivonescimab’s global development path and could broaden the asset’s use in ADC combinations. For Akeso, stronger ex-China development momentum could support retained China economics, royalty and milestone potential, and market perception of the program.

Risks

• Pipeline development setbacks could undermine Akeso’s rating and price target.
• Sales of AK104 or AK112 below JPMorgan’s expectations would be a downside risk.
• The November 14 PDUFA decision and HARMONi-3 final PFS data could produce negative headline risk for Summit and ivonescimab.

What to watch

• Details of the AZN/Summit combination-trial design, including potential pairing of ivonescimab with the CLDN18.2 ADC Sone-Ve in first-line gastric cancer.
• HARMONi-GI1 Phase 3 biliary tract cancer data at the ESMO 2026 Presidential Symposium II on October 25, particularly the overall-survival hazard ratio.
• The November 14 PDUFA date for ivonescimab in second-line-or-later EGFR-positive NSCLC.
• Final Phase 3 PFS data from the HARMONi-3 squamous NSCLC cohort in 4Q26.
• Any indication that AstraZeneca and Summit may deepen their clinical collaboration.